MNG Laboratories, Pronto Diagnostics Partner to Offer Clinical RNA Sequencing Services in Israel
The RNA Sequencing Services portfolio includes the MNG Transcriptome™ complete RNA transcriptome sequencing, Gene-Specific RNA Sequencing for the analysis of one or up to five genes for variant investigation following a report with a VUS identified in a splice site or intronic region and Panel-Specific RNA Sequencing which is transcriptome analysis of a target set of genes included in a targeted next generation sequencing panel.
“We are excited to add RNA sequencing services to our portfolio of testing services in Israel. We chose MNG due to their experience and leadership in rare disease diagnostics. Having the ability to offer this important set of tests helps us to ensure we offer the best diagnostic tools to our clients”, noted Nir Navot, CEO of Pronto Diagnostics.
A recent study in Science Translational Medicine reported that RNA sequencing was able to provide a diagnosis in 35% of patients with muscle disorders that could not be diagnosed by DNA sequencing alone (PMID: 28424332) and patients with other types of disorders are also likely to benefit from this testing. Additionally, this testing can be used to determine what effect, if any, variants of uncertain significance (VUS) may have on transcription.
“This partnership with Pronto is an important addition to the expansion strategy at MNG to bring our portfolio of world class neurogenetic testing to the global rare disease diagnostic market,” noted Humberto Huerta, Senior Director of Business Development at MNG.
Under the Distribution Agreement, testing will be performed at MNG's CLIA and CAP-accredited laboratory and a clinical report will be delivered in as fast as 2-4 weeks.
About MNG Laboratories
MNG Laboratories is an internationally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing. We are committed to a patient-centered testing menu, high-quality diagnostics, and first-in-class reporting driven by our Genome MaNaGer® analysis pipeline. Our Neurogenetic Answers™ reporting process helps us stay at the forefront of the evolving genetics field. Our team-based approach to data interpretation ensures we provide actionable results on the variants that cause or are likely to cause disease. Our comprehensive approach to diagnostics is accompanied by a team of customer support and scientific personnel available to answer your questions regarding our process, technology, and reports. With over 16 years of neurogenetic experience, and powered by a culture of discovery and advancement, MNG Laboratories delivers results that make a difference for patients and their families.
More information about MNG Laboratories can be found at mnglabs.com.
About Pronto Diagnostics
Pronto Diagnostics is a leader in molecular diagnostics in Israel, since its establishment in 1993. In its early days the company was one of the first companies globally to develop clinical diagnostic kits for mutation detection; over the years it has developed more than 35 CE IVD-marked kits for the diagnosis of mutations causing a variety of diseases. Pronto Diagnostics is distributing products and unique devices from leading international manufacturers; it operates a molecular clinical diagnostic laboratory, accredited by the Israeli Ministry of Health, that is ISO 9001:2015 and ISO 27799 certified. It provides both clinical diagnostics and clinical research services, which include DNA purification; sequencing and deletion/duplication analysis for any gene; fragment analysis; pharmacogenetic testing and epigenetic tests. ProntoLab™ carries out sequencing and data analysis of whole-exome, as well targeted gene panels for specific diseases and syndromes. Pronto represents in Israel some of the leading international service providers, it offers their tests in addition to its own services to Israeli institutional customers as well as to the private diagnostic market.
Source: MNG Laboratories